Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)

References

• Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386(10003):1565–1575.
   PubMed Web of Science ®Google Scholar
• James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology. 1999;30(2):390–394.
   PubMed Web of Science ®Google Scholar
• Annual report on liver transplantation: Report for 2019/2020. 2020, NHS Blood and Transplant.
   Google Scholar
• Carbone M, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560–569 e7; quiz e13–4.
   Web of Science ®Google Scholar
• Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):318–328.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, et al. The British society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568–1594.
   PubMed Web of Science ®Google Scholar
• Jacoby A, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11):1622–1629.
   PubMed Web of Science ®Google Scholar
• Hegade VS, et al. P1152: a comparative study of pruritus in PBC cohorts from UK, USA and Italy. J Hepatol. 2015;62:S785.
   Web of Science ®Google Scholar
• Dyson JK, et al. Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015;62(1):208–218.
   PubMed Web of Science ®Google Scholar
• Khanna A, Jopson L, Howel D, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial. Hepatology. 2019;70(5):1646–1657.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-Controlled Trial of Bezafibrate in primary Biliary Cholangitis. N Engl J Med. 2018;378(23):2171–2181.
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A Placebo-Controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–643.
   PubMed Web of Science ®Google Scholar
• Newton JL, Gibson GJ, Tomlinson M, et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology. 2006;44(1):91–98.
   PubMed Web of Science ®Google Scholar
• Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58(1):273–283.
   PubMed Web of Science ®Google Scholar
• Montagnese S, Nsemi LM, Cazzagon N, et al. Sleep-Wake profiles in patients with primary biliary cirrhosis. Liver Int. 2013;33(2):203–209.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361–1367.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871–877.
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130(3):715–720.
   PubMed Web of Science ®Google Scholar
• Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281–1287.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Brunt EM, Heathcote J, et al., American association for the study of liver diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52(1): 349–359.
   PubMed Web of Science ®Google Scholar
• Momah N, Silveira MG, Jorgensen R, et al., Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012;32(5): 790–795.
   PubMed Web of Science ®Google Scholar
• Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol. 2003;1(2):89–95.
   PubMed Web of Science ®Google Scholar
• Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 1979;20(2):137–140.
   PubMed Web of Science ®Google Scholar
• Krzeski P, et al. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology. 1999;30(4):865–869.
   PubMed Web of Science ®Google Scholar
• Trauner M, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4(6):445–453.
   PubMed Web of Science ®Google Scholar
• Compendium (E.m.c) EM. OCALIVA 5mg film-coated tablets. 2018 23/03/2018 [cited 2022 May 10]; Available from: https://www.medicines.org.uk/emc/product/2561/smpc#gref.
   Google Scholar
• Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–2196.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751–761.e8.
   PubMed Web of Science ®Google Scholar
• Dash A, et al. Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol in vitro. 2017;39:93–103.
   PubMed Web of Science ®Google Scholar
• Eaton JE, et al. Liver injury in patients with cholestatic liver disease treated with obeticholic acid. Hepatology. 2020;71(4):1511–1514.
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009;2009:501739.
   PubMed Web of Science ®Google Scholar
• Burns K, Vandenheuvel J. Modulation of PPAR activity via phosphorylation. Biochimica Et Biophysica Acta (BBA) - Mol Cell Biol Lipids. 2007;1771(8):952–960.
   PubMed Web of Science ®Google Scholar
• Reig A, Sese P, Pares A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol. 2018;113(1):49–55.
   PubMed Web of Science ®Google Scholar
• Hosonuma K, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110(3):423–431.
   PubMed Web of Science ®Google Scholar
• Sica DA. Fibrate therapy and renal function. Curr Atheroscler Rep. 2009;11(5):338–342.
   PubMed Web of Science ®Google Scholar
• Ansquer JC, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51(6):904–913.
   PubMed Web of Science ®Google Scholar
• Hottelart C, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92(3):536–541.
   PubMed Web of Science ®Google Scholar
• De Vries E, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology; 2020.
   Google Scholar
• Tanaka A, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021.
   Web of Science ®Google Scholar
• Jones D, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2(10):716–726.
   PubMed Web of Science ®Google Scholar
• Bays HE, et al. MBX-8025. J Clin Endocrinol Metab. 2011;96(9):2889–2897.
   PubMed Web of Science ®Google Scholar
• Xia X, et al. Liver X receptor β and peroxisome proliferator-activated receptor δ regulate cholesterol transport in murine cholangiocytes. Hepatology. 2012;56(6):2288–2296.
   PubMed Web of Science ®Google Scholar
• Kouno T, et al. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. J Biol Chem. 2022;298(7):102056.
   PubMed Web of Science ®Google Scholar
• Peters JM, et al. Peroxisome proliferator-activated receptor is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis. 2000;21(4):823–826.
   PubMed Web of Science ®Google Scholar
• Dubois V, et al. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Investig. 2017;127(4):1202–1214.
   PubMed Web of Science ®Google Scholar
• Iwaisako K, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor agonist. Proc Nat Acad Sci. 2012;109(21):E1369–E1376.
   PubMed Web of Science ®Google Scholar
• Boudes P, et al. Pharmacokinetics and pharmacodynamics of seladelpar, a potent and selective PPAR-delta, in patients with primary biliary cholangitis. J Hepatol. 2018;68.
   Web of Science ®Google Scholar
• Mao L, et al. FRI-041-Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment. J Hepatol. 2019;70(1).
   Web of Science ®Google Scholar
• Levy C, et al. Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. J Hepatol. 2020;73:S464–S465.
   PubMed Web of Science ®Google Scholar
• Bowlus CL, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol; 2022:77(2):353-364.
   Google Scholar
• ENHANCE: safety and efficacy of seladelpar in patients with primary biliary cholangitis-a phase 3, international, randomized, placebo-controlled study. Gastroenterol Hepatol. 2021; 17(2 Suppl 3): 5–6.
   Google Scholar
• Kremer AE, Mayo MJ, Hirschfield G, et al. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International; 2022;42(1):112-123.
   Google Scholar
• Watkins P, et al. An independent blinded review of suspected drug-induced liver injury (Dili) in non-alcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatoxicity review committee (SHRC). J Hepatol. 2021;29:1043. Elsevier Radarweg NX Amsterdam, Netherlands.
   Google Scholar
• Gordon SC, Bowlus C TP, Michael G, et al. Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies. J Hepatol. 2021;75:S686-S687.
   Web of Science ®Google Scholar
• Davidson MH, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6):S3–S18.
   PubMedGoogle Scholar